Publication date: November 2026 Source: Heart Rhythm, Volume 23, Issue 11 Author(s): Jens Van fraeyenhove, Michiel R.L. Tubeeckx, Bo Goovaerts, Yile Fu, Juan Zhang, Sven O. Dekker, Arthur Bezerra, Tim De Coster, Julie Cools, Eike M. Wülfers, Siel Van den Bogaert, Tine Bruyns, Bernard Thienpont, Samuel L. Murphy, Antoine A.F. de Vries, Erik Fransen, Nele Vandersickel, Daniël A. Pijnappels, Guido R.Y. De Meyer, Hein Heidbuchel
ERBB4 activation as a new therapy for atrial remodeling and fibrillation. // Heart Rhythm. – URL: https://www.sciencedirect.com/science/article/pii/S1547527126023404?dgcid=rss_sd_all
ERBB4 activation as a new therapy for atrial remodeling and fibrillation. Heart Rhythm. https://www.sciencedirect.com/science/article/pii/S1547527126023404?dgcid=rss_sd_all
“ERBB4 activation as a new therapy for atrial remodeling and fibrillation.” Heart Rhythm.
@article{article48098,
title = {ERBB4 activation as a new therapy for atrial remodeling and fibrillation},
journal = {Heart Rhythm},
url = {https://www.sciencedirect.com/science/article/pii/S1547527126023404?dgcid=rss_sd_all}
}
ABSTRACT Introduction/Aims Pompe disease is a genetic myopathy caused by acid alpha‐glucosidase enzyme deficiency. Treatment response is mainly evaluated using motor scores, for instance the 6‐min walk test (6MWT) or the Motor Function...
ABSTRACT Introduction/Aims Inflammatory neuropathies (IN), such as Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are characterized by peripheral nerve injury driven by immune...